Study of Subclinical Viral Infection
Subclinical Viral Infection and Renal Allograft Injury
1 other identifier
observational
100
1 country
1
Brief Summary
Chronic allograft injury is the leading cause of graft loss in renal transplantation. The shortage of available kidneys for transplantation has reached crisis levels with increasing numbers of waiting list mortalities. Strategies to prolong graft survival are urgently needed. The pediatric and young adult transplant population is one in which repeat transplantation is inevitable and therefore, this group is one who will especially benefit from intervention to prolong graft survival. The hypothesis of this proposal is that subclinical viral infection is a modifiable risk factor in the pathogenesis of chronic allograft injury. The young age of the proposed study population is an ideal one to evaluate this objective due to the high prevalence of seronegative recipients. The studies outlined will determine the temporal relationship betWeween subclinical viremia, renal allograft infection and allograft injury. This will be the first prospective study in renal transplant recipients to systematically monitor subclinical viral infection both in peripheral blood and in the renal allograft with concurrent quantitative measures of renal function, allograft fibrosis, and innate immune activation. The investigators have chosen these 3 outcomes because they evaluate a spectrum of renal allograft injury and represent different stages - from early to late - in the pathophysiology that leads to renal allograft dysfunction. In addition, the role of virus specific T cell immune responses in the control of subclinical viral infection and associated allograft injury will be determined. These data are critical as they will provide insights into the pathogenesis of injury and will guide development of interventions strategies. Importantly, the current treatment strategies for viral disease do not prevent subclinical viral infection. Thus, the results of this study may identify that prevention, prophylaxis and/or treatment of subclinical viral replication as a long term strategy to prevent chronic allograft injury and prolong graft survival.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Oct 2011
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2011
CompletedFirst Submitted
Initial submission to the registry
June 6, 2012
CompletedFirst Posted
Study publicly available on registry
June 8, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2016
CompletedJune 8, 2012
June 1, 2012
5 years
June 6, 2012
June 7, 2012
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in measured GFR from baseline
Single infusion of iohexol clearance to measure GFR
time of transplant, one time between months 3 and 6, and during months 12, and 24 after the transplant
Secondary Outcomes (2)
Change in interstitial fibrosis and tubular atrophy of renal allograft from baseline
Renal biopsies will be performed at time of transplant, 3-6 m, 12m, and 24m post-transplant. Precise measures of renal function, allograft fibrosis, and innate immune activation will be performed at baseline, 6m, 12, 24m post-transplant.
Change in innate immune activation of renal allograft from baseline
6, 12, and 24 months after the transplant
Eligibility Criteria
Pediatric and young adult renal transplant recipients (1\<25yrs) of their first kidney transplant from Seattle Children's Hospital and University of Washington Medical Center.
You may qualify if:
- Subject and/or parent guardian must be able to understand and provide informed consent or assent
- Male or Female, Seattle Children's Hospital participants must be 1-\<21 yrs and University of Washington Medical Center participants 18-25yrs.
- Diagnosed with End Stage Renal Disease (ESRD)
You may not qualify if:
- Inability or unwillingness of subject and/or parent guardian to provide informed consent
- Pregnancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Seattle Children's Hospitallead
- University of Washingtoncollaborator
Study Sites (1)
Seattle Children's Hospital
Seattle, Washington, 98105, United States
Biospecimen
If participant agrees, blood, tissue, and study data will be banked at Seattle Children's Research Institute.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jodi Smith, MD
Seattle Children's Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant Professor
Study Record Dates
First Submitted
June 6, 2012
First Posted
June 8, 2012
Study Start
October 1, 2011
Primary Completion
October 1, 2016
Study Completion
October 1, 2016
Last Updated
June 8, 2012
Record last verified: 2012-06